Compare · IQV vs OABI
IQV vs OABI
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $43.13B, about 65.2x OABI ($661.5M).
- Over the past year, IQV is up 28.5% and OABI is up 169.4% - OABI leads by 140.9 points.
- IQV has been more active in the news (6 items in the past 4 weeks vs 2 for OABI).
- IQV has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- IQVIA Holdings Inc.
- OmniAb Inc.
- Price
- $264.57-2.44%
- $4.58-3.17%
- Market cap
- $43.13B
- $661.5M
- 1M return
- -1.83%
- +3.27%
- 1Y return
- +28.47%
- +169.41%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2021
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 5
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest IQV
- IQVIA Selects Veeva Clinical Operations Applications
- IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
- IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
- UBS resumed coverage on IQVIA with a new price target
- IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- IQVIA Announces Offering of Senior Notes
- Officer Berkshire James G. exercised 5,381 shares at a strike of $131.82, sold $697,228 worth of shares (2,668 units at $261.33) and returned $709,558 worth of shares to the company (2,713 units at $261.54) (SEC Form 4)
Latest OABI
- OmniAb to Report Third Quarter 2026 Financial Results on October 30
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
- OmniAb to Host Investor & Analyst Day on October 6, 2026
- OmniAb to Participate in Upcoming Investor Conferences
- OmniAb Raises 2026 Financial Guidance
- OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
- SEC Form 4 filed by Chief Operating Officer Nwachuku Amechi Ekeke